

NOT FOR DISTRIBUTION, RELEASE OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), CANADA, AUSTRALIA OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, RELEASE OR PUBLICATION WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE DOCUMENT.

MARKETING ACCORDING TO THE PROSPECTUS REGULATION (EU) 2017/1129.

Rights issue Q&A in Swedish Orphan Biovitrum AB (publ) ("Sobi" or the "Company")

Please note that the following questions and answers provide general answers to frequently asked questions in connection with a rights issue. Investors are encouraged to read the prospectus of the rights issue before making an investment decision in order to fully understand the potential risks associated with a decision to invest in the securities (see the section "Risk Factors" of the prospectus). When investors make an investment decision, they must rely on their own analysis of Sobi and the offering in accordance with the prospectus, including applicable facts and risks. Before making an investment decision, investors should engage professional advisors and carefully evaluate and consider the investment decision. Investors may only rely on the information in the prospectus and any supplements to the prospectus. The prospectus is available on Sobi's website, www.sobi.com/en/rights-issue-2023.

SHAREHOLDERS WHO HAVE HOLDINGS THAT ARE NOMINEE-REGISTERED ARE REFERRED TO THEIR RESPECTIVE NOMINEES FOR INFORMATION AND INSTRUCTIONS.

Background

1. Why does Sobi carry out a rights issue?

On 10 May 2023, Sobi announced that the Company had entered into an agreement, under which Sobi agreed to submit a cash tender offer for all the shares in CTI BioPharma Corp. ("CTI") for a purchase price of USD 1,684 million (corresponding to SEK 18,060 million¹). The acquisition was completed on 26 June 2023 after successful completion of the tender offer.

The acquisition of CTI has been funded through bank financing corresponding to a total of SEK 17,350² million, of which SEK 8,000 million consists of a bridge loan provided by Bank of America Europe Designated Activity Company and Danske Bank. The net proceeds from the rights issue will be used to repay part of the bridge loan, which will strengthen Sobi's financial position and enable continued future investments, including further acquisitions, for the implementation of the Company's strategy.

2. How large is the rights issue?

Assuming that the rights issue is fully subscribed, issue proceeds will amount to approximately SEK 6,024 million before deduction of transaction costs (estimated to amount to approximately SEK 70 million).

¹ Based on an USD/SEK rate of 10.7217 as of 26 June 2023.

² The total amount of approximately SEK 17,350 million (based on an EUR/SEK rate of 11.6837 as of 26 June 2023) consists of long-term debt financing of EUR 800 million and the bridge Loan of SEK 8,000 million.

Commitments from current owners

1. Is the rights issue fully covered by subscription commitments and / or underwriting commitments?

The Company's largest shareholder Investor AB (publ), representing approximately 36.2³ per cent of the shares in the Company, has undertaken to subscribe for its pro rata share of the rights issue. In addition, Fjärde AP-fonden, Polar Capital, Handelsbanken Fonder, Swedbank Robur Fonder and Nordea Investment Management AB acting on behalf of its underlying clients, together representing approximately 13.5⁴ per cent of the shares in the Company, have expressed their intention to subscribe for their respective pro rata share of the rights issue based on the shares held at the record date of the rights issue.

Hence, the rights issue is covered to 49.7⁵ per cent through subscription commitments and declarations of intent to subscribe. None of these commitments are secured by, for example, a bank guarantee or similar arrangement.

Rights issue basics and additional information

1. What is a rights issue?

A rights issue is an offering to all existing shareholders to subscribe for new shares in the company to a predetermined price and during a shorter time period. The rights issue will provide cash and equity to the company's balance sheet. Registered shareholders in Sobi on the record date 29 August 2023 (and who are not legally restricted from participating) will receive subscription rights with preferential right to subscribe for new shares in the rights issue in proportion to their existing shareholdings.

2. As a shareholder in Sobi, do I need to do anything to receive subscription rights in the rights issue?

No, all registered shareholders in Sobi on the record date 29 August 2023 will automatically receive subscription rights (with the exception of shareholders who are legally restricted from participating in the rights issue).

Please note that if you have your shares with nominees (through custody accounts or other account type), refer to your respective nominees for information on how to subscribe for shares with preferential rights.

3. What is the record date?

The record date is the day on which you must be registered as a shareholder in order to be allocated subscription rights. If you were not a registered shareholder on the record date 29 August 2023 you will not receive any subscription rights. Shares traded from and including the trading day before the record date (28 August 2023) do not include the right to participate in the rights issue.

4. What is a subscription right?

A subscription right is a security that gives the holder the right to subscribe for new shares in a company for a certain period at a certain price. The subscription right has an economic value if the subscription price is lower than the share price.

5. What if I do not do anything?

Then you risk losing the potential value of your subscription rights. To avoid this you must:

³ Excluding Sobi's holdings of treasury shares. As of 22 August 2023, Sobi held 14,399,118 treasury common shares.

⁴ Excluding Sobi's holdings of treasury shares. As of 22 August 2023, Sobi held 14,399,118 treasury common shares.

⁵ Excluding Sobi's holdings of treasury shares. As of 22 August 2023, Sobi held 14,399,118 treasury common shares.

- exercise your subscription rights and subscribe for new shares before the subscription period ends (14 September 2023); or
- sell your subscription rights before the subscription rights trading period ends (11 September 2023).

6. When can I subscribe for new shares in the rights issue?

The subscription period will take place during the period from and including 31 August 2023 up to and including 14 September 2023. Subscription of new shares with the exercise of subscription rights and application for subscription of new shares without preferential rights must be made during the subscription period.

Please note that if you have your shares with nominees (through custody accounts or other account type), the nominee may have different dates for when you must have registered for subscription of new shares (with or without the support of subscription rights).

7. How many subscription rights do I need to subscribe for new shares?

Seven (7) subscription rights confers the right to subscribe for one (1) new share.

8. To which price can I subscribe for new shares?

The subscription price has been set to SEK 142 per new share.

9. Can I subscribe for more shares than I have received subscription rights for?

Yes, that can be done in the following ways:

- i. You may buy more subscription rights on Nasdaq Stockholm during the trading period for subscription rights. The last day for buying subscription rights is 11 September 2023.
- ii. You can also apply to subscribe for shares without the exercise of subscription rights. In such case, you are not guaranteed allocation of new shares.

10. How do I buy or sell subscription rights?

You can contact your bank or your nominee for instructions or buy and sell subscription rights over the stock exchange during the period from and including 31 August 2023 up to and including 11 September 2023.

11. Which shareholders should use the preprinted bank giro form?

Directly registered shareholders residing in Sweden will receive the pre-printed issue statement with attached bank giro form sent by mail. If you wish to participate in the rights issue as a directly registered shareholder, and use all the subscription rights shown in the issue statement, use the preprinted bank giro form at the bottom of the issue statement. No additions or amendments may be made to the text preprinted on the payment slip, i.e. the payment must correspond to the exact amount stated on the bank giro form. Directly registered authorised shareholders who are not residents in Sweden and who cannot use the preprinted issue statement can instead use a subscription form. Shareholders with nominee-registered holdings will not receive a preprinted issue statement with attached bank giro form, but are asked to turn to their nominee for instructions on participation in the rights issue.

12. When should I, as a directly registered shareholder, use the subscription form?

If you are a directly registered shareholder (and not a resident in a restricted jurisdiction) and want to participate in the rights issue, but want to use a different number of subscription rights than those listed on the preprinted issue statement, for example if you have purchased or sold subscription rights, use a subscription form. If you are a directly registered shareholder who is not resident in

Sweden and not subject to the restrictions for unauthorised jurisdictions (see question 20), but who is unable to use the pre-printed bank giro form, you should use the subscription form.

The subscription form is available at <https://www.sobi.com/en/rights-issue-2023> and www.danskebank.se/prospekt.

13. How do I, as a directly registered shareholder, pay for the new shares?

If you are a directly registered shareholder residing in Sweden who uses the preprinted bank giro form on the issue statement, you can pay just as you pay your regular bills, for example via Bankgiro, Plusgiro, internet bank or at the nearest branch. If you use the subscription form, you can pay via your internet bank (and then submit the subscription form).

If you are a directly registered shareholder who is not resident in Sweden and not subject to the restrictions for unauthorised jurisdictions, but who is unable to use the pre-printed bank giro form you should pay in accordance with the instructions in the application form.

14. What happens after I have subscribed and paid for my new shares?

When your subscription and payment of new shares with the exercise of subscription rights are registered in the Euroclear system, paid subscribed shares (Sw: "Betald tecknade aktier", so called "BTA", see below) will be booked on your account. When the rights issue is registered with the Swedish Companies Registration Office, your paid subscribed shares is automatically converted into ordinary shares.

Shares subscribed for without the exercise of subscription rights will be delivered to your account when the rights issue is registered with the Swedish Companies Registration Office. For these shares, no BTAs will be booked into your account.

15. What is a paid subscribed share ("BTA")?

A BTA, paid subscribed share, is a temporary share that exists for a limited period. Those who subscribe for shares with exercise of subscription rights will, when subscription and payment for the shares have been completed, receive BTAs until the shares subscribed for with exercise of subscription rights have been registered with the Swedish Companies Registration Office. BTAs will thereafter be converted into new shares. BTAs obtained as a result of the exercise of subscription rights will be traded on Nasdaq Stockholm

16. When can I trade with BTAs?

Trading in BTAs will take place from and including 31 August 2023, up to and including 26 September 2023 on Nasdaq Stockholm. During this period it is possible to buy and sell BTAs. Contact your bank or nominee for instructions on trading in BTA.

17. How do I subscribe for shares without the support of subscription rights?

For directly registered shareholders, the application to subscribe for new shares without subscription rights must be made on the relevant subscription form marked "Teckning av aktier utan stöd av teckningsrätter" (Eng. "Subscription for shares without subscription rights"), which is available on Sobi's website, www.sobi.com/en/rights-issue-2023, and on Danske Bank's website, www.danskebank.se/prospekt, before the subscription period ends.

If not all of the new shares have been subscribed for with subscription rights, Sobi's Board of Directors shall make a decision on the allocation of new shares without subscription rights. Shares must be allocated as follows within the framework of the maximum amount of the rights issue and subject to

the restrictions set out in “*Selling and transfer restrictions*” in the prospectus published on 28 August 2023:

- Firstly, to those who subscribed for shares with subscription rights and who applied to subscribe for additional new shares, whether they were shareholders on the record date or not, and, in the event of oversubscription, pro rata in proportion to the number of shares that such persons subscribed for in the rights issue with subscription rights, or, to the extent not possible, through the drawing of lots.
- Secondly, to those who applied to subscribe for new shares without subscription rights (the general public in Sweden and Denmark as well as “qualified investors”), and, in the event of oversubscription, pro rata in relation to the number of shares stated in the respective application form, or, to the extent not possible, through the drawing of lots.

As confirmation of allocation of new shares subscribed for without subscription rights, a contract note will be sent to the subscriber on or around 20 September 2023. No communication will be sent to subscribers who have not been allocated shares.

Notification of any allocation for holdings in custody is obtained in accordance with procedures of your bank or nominee, which will be informed by Danske Bank.

18. How do I proceed if my holdings are nominee-registered?

Shareholders whose holdings are registered with a bank or other nominee will not receive an issue statement with attached bank giro form. Subscription and payment of new shares with or without support of subscription rights shall be done by the respective nominee and in accordance with instructions from the nominee.

19. Can I withdraw my application if I regret to participate in the rights issue?

No, the application is binding.

20. Which jurisdictions are restricted and why is this the case?

Allotment of subscription rights and the issuance of new shares to individuals and entities in countries other than Sweden and Denmark may be affected by securities legislation in such countries. Accordingly, with certain exceptions, shareholders residing in, for example, Australia, Hong Kong, Japan, Canada, Singapore, South Africa, the United States or any other jurisdiction where participation would require an additional prospectuses, registration or measures beside those required by Swedish or Danish law, will not receive any subscription rights or be allowed to subscribe for new shares.

21. What should I do if I reside in a restricted jurisdiction?

If you are a directly registered shareholder resident in a restricted jurisdiction, the subscription rights that otherwise would have been allotted to you will instead be sold and the sales proceeds, less a deduction for costs, will be paid out. Danske Bank intends to attempt to effectuate such sales from and including 31 August 2023 up to and including 11 September 2023, provided that there are buyers in the market. Sales proceeds below SEK 100 will be paid out upon request.

Please note that if you have your shares with nominees (through custody accounts or other account type), refer to your respective nominees for information on the nominee’s procedures.

22. Where can I find complete terms and conditions for the rights issue?

The terms and conditions of, and information on, the rights issue and Sobi are available in the prospectus relating to the rights issue, which is available on Sobi’s website,

www.sobi.com/en/rights-issue-2023, as well as on Danske Bank's website, www.danskebank.se/prospekt.

This document is an English translation of the Swedish original. In the event of any discrepancies, the Swedish version shall govern.

IMPORTANT NOTICE

*These materials may not be published, distributed or transmitted in the United States, Canada, Australia, Japan or any other jurisdiction in which the distribution, release or publication would be unlawful. These materials do not constitute an offer of securities for sale or a solicitation of an offer to purchase securities (the "**Securities**") of Swedish Orphan Biovitrum AB (publ) (the "**Company**") in the United States or any other jurisdiction in which such offer or solicitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation. The Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "**Securities Act**"). The Securities have not been, and will not be, registered under the Securities Act. There will be no public offer of securities in the United States.*

The Securities have not been and will not be registered under the applicable securities laws of Australia, Japan, Canada, Hong Kong, Singapore, South Africa or any other jurisdiction in which it would be unlawful or would require registration or other measures, and therefore may not be offered, subscribed for, used, pledged, sold, resold, allotted, delivered or otherwise transferred, directly or indirectly, or for the account or benefit of any person having a registered address in, or located or resident in, Australia, Japan, Canada, Hong Kong, Singapore, South Africa or any other jurisdiction in which it would be unlawful or would require registration or other measures.

*In any Member State of the European Economic Area ("**EEA**"), other than Sweden or any EEA Member State to which the prospectus is passported under the Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "**Prospectus Regulation**"), this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of Regulation (EU) 2017/1129 ("**Qualified Investors**"), and no person outside of Sweden or any EEA Member State to which the prospectus is passported under the Prospectus Regulation, that is not a relevant person or a Qualified Investor may act or rely on these materials or any of its contents.*

*In the United Kingdom, this document is being distributed to and is directed only at qualified investors, within the meaning under Article 2(e) of Regulation (EU) 2017/1129 as it forms part of English law by virtue of the European Union (Withdrawal) Act 2018 as amended from time to time, who are also (i) persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**") or (ii) high net worth entities, or other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order, (all such persons together being referred to as "**relevant persons**"). The Securities are only available in the United Kingdom to, and any invitation, offer or agreement to purchase or otherwise acquire the Securities will be engaged in only with, the relevant persons. Any person in the United Kingdom that is not a relevant person should not act or rely on this document or any of its contents.*

The document is for informational purposes only and does not constitute an offer to sell or issue, or the solicitation of an offer to buy or acquire, or subscribe for, any of the Securities. Invitation to the persons concerned to subscribe for shares in the Company will only be made by means of the prospectus that the Company published on 28 August 2023 at the Company's website. The prospectus, which has been approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen), is available at the company's website www.sobi.com/en/rights-issue-2023. The approval of the prospectus by the Swedish Financial Supervisory Authority should not be understood as an endorsement of the securities offered or admitted to trading on a regulated market. This document has not been approved by any regulatory authority and is not a prospectus.

Not for release, publication or distribution in the United States, Australia, Canada or Japan.

Investors should not subscribe for or purchase any securities referred to in this document except on the basis of information contained in the prospectus. Potential investors should read the prospectus before making an investment decision in order to fully understand the potential risks associated with a decision to invest in the securities (see "Risk factors" in the prospectus).

This document contains certain forward-looking statements with respect to certain of the Company's current expectations and projections about future events. These statements, which sometimes use words such as "intend," "proposed," "plan," "expect," and words of similar meaning, reflect management's beliefs and expectations and involve a number of risks, uncertainties and assumptions (including the completion of the transactions described in this document) that could cause actual results and performance to differ materially from any expected future results or performance expressed or implied by the forward-looking statement. Statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The information contained in this document is subject to change without notice and, except as required by applicable law, the Company does not assume any responsibility or obligation to update publicly or review any of the forward-looking statements contained in it. Readers should not place undue reliance on forward-looking statements, which speak only as at the date of this document.